Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models
Author: Morrish, E.
Copeland, A.
Moujalled, D.M.
Powell, J.A.
Silke, N.
Lin, A.
Jarman, K.E.
Sandow, J.J.
Ebert, G.
Mackiewicz, L.
Beach, J.A.
Christie, E.L.
Lewis, A.C.
Pomilio, G.
Fischer, K.C.
MacPherson, L.
Bowtell, D.D.L.
Webb, A.I.
Pellegrini, M.
Dawson, M.A.
et al.
Citation: Blood Advances, 2020; 4(20):5062-5077
Publisher: American Society of Hematology
Issue Date: 2020
ISSN: 2473-9529
Statement of
Emma Morrish, Anthony Copeland, Donia M. Moujalled, Jason A. Powell, Natasha Silke, Ann Lin ... et al.
Abstract: The specific targeting of inhibitor of apoptosis (IAP) proteins by Smac-mimetic (SM) drugs, such as birinapant, has been tested in clinical trials of acute myeloid leukemia (AML) and certain solid cancers. Despite their promising safety profile, SMs have had variable and limited success. Using a library of more than 5700 bioactive compounds, we screened for approaches that could sensitize AML cells to birinapant and identified multidrug resistance protein 1 inhibitors (MDR1i) as a class of clinically approved drugs that can enhance the efficacy of SM therapy. Genetic or pharmacological inhibition of MDR1 increased intracellular levels of birinapant and sensitized AML cells from leukemia murine models, human leukemia cell lines, and primary AML samples to killing by birinapant. The combination of clinical MDR1 and IAP inhibitors was well tolerated in vivo and more effective against leukemic cells, compared with normal hematopoietic progenitors. Importantly, birinapant combined with third-generation MDR1i effectively killed murine leukemic stem cells (LSCs) and prolonged survival of AML-burdened mice, suggesting a therapeutic opportunity for AML. This study identified a drug combination strategy that, by efficiently killing LSCs, may have the potential to improve outcomes in patients with AML.
Keywords: Hematopoiesis and stem cells; myeloid neoplasia
Rights: © 2020 by The American Society of Hematology
DOI: 10.1182/bloodadvances.2020001576
Grant ID:
Published version:
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.